WO2003015810A1 - Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale - Google Patents

Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale Download PDF

Info

Publication number: WO2003015810A1
Authority: WO; WIPO (PCT)
Prior art keywords: histone deacetylase; deacetylase inhibitor; antitumor effect; medicinal use; evaluating
Prior art date: 2001-08-21

Application number

PCT/JP2002/008355

Other languages

English (en)

French (fr)

Inventor

Yuka Sasakawa

Yoshinori Naoe

Original Assignee

Fujisawa Pharmaceutical Co., Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-21

Filing date

2002-08-20

Publication date

2003-02-27

2002-08-20 Application filed by Fujisawa Pharmaceutical Co., Ltd. filed Critical Fujisawa Pharmaceutical Co., Ltd.

2002-08-20 Priority to HU0400668A priority Critical patent/HU229521B1/hu

2002-08-20 Priority to JP2003520768A priority patent/JP4238728B2/ja

2002-08-20 Priority to DK02760663.1T priority patent/DK1426054T3/da

2002-08-20 Priority to AT02760663T priority patent/ATE526029T1/de

2002-08-20 Priority to US10/486,833 priority patent/US8470783B2/en

2002-08-20 Priority to EP02760663A priority patent/EP1426054B1/en

2002-08-20 Priority to MXPA04001612A priority patent/MXPA04001612A/es

2002-08-20 Priority to CA002457043A priority patent/CA2457043A1/en

2003-02-27 Publication of WO2003015810A1 publication Critical patent/WO2003015810A1/ja

2004-02-20 Priority to NO20040731A priority patent/NO331682B1/no

Links

229940121372 histone deacetylase inhibitor Drugs 0.000 title abstract 3
239000003276 histone deacetylase inhibitor Substances 0.000 title abstract 3
230000000259 anti-tumor effect Effects 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
206010025323 Lymphomas Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Zoology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Wood Science & Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Toxicology (AREA)

PCT/JP2002/008355 2001-08-21 2002-08-20 Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale WO2003015810A1 (fr)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
HU0400668A HU229521B1 (hu)	2001-08-21	2002-08-20	A hiszton-dezacetiláz inhibitor gyógyászati alkalmazása, és eljárás tumorellenes hatásának kiértékelésére
JP2003520768A JP4238728B2 (ja)	2001-08-21	2002-08-20	ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法
DK02760663.1T DK1426054T3 (da)	2001-08-21	2002-08-20	Medicinsk anvendelse af histon-deacetylase-inhibitor og fremgangsmåde til evaluering af antitumor virkning deraf
AT02760663T ATE526029T1 (de)	2001-08-21	2002-08-20	Medizinische verwendung eines histon-deacetylase- hemmers und verfahren zur beurteilung seiner antitumoralen wirkung
US10/486,833 US8470783B2 (en)	2001-08-21	2002-08-20	Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
EP02760663A EP1426054B1 (en)	2001-08-21	2002-08-20	Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
MXPA04001612A MXPA04001612A (es)	2001-08-21	2002-08-20	Uso medicinal de inhibidor de la histona desacetilasa y metodo para evaluar el efecto antitumoral del mismo.
CA002457043A CA2457043A1 (en)	2001-08-21	2002-08-20	Medicinal use of histone deacetylase inhibitor and method of evaluating antitumor effect thereof
NO20040731A NO331682B1 (no)	2001-08-21	2004-02-20	Medisinsk anvendelse av histon-deacetylase inhibitor.

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2001250846		2001-08-21
JP2001-250846		2001-08-21

Publications (1)

Publication Number	Publication Date
WO2003015810A1 true WO2003015810A1 (fr)	2003-02-27

Family

ID=19079582

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PCT/JP2002/008355 WO2003015810A1 (fr)	2001-08-21	2002-08-20	Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale

Country Status (14)

Country	Link
US (1)	US8470783B2 (ja)
EP (1)	EP1426054B1 (ja)
JP (1)	JP4238728B2 (ja)
AT (1)	ATE526029T1 (ja)
CA (1)	CA2457043A1 (ja)
DK (1)	DK1426054T3 (ja)
ES (1)	ES2371630T3 (ja)
HU (1)	HU229521B1 (ja)
MX (1)	MXPA04001612A (ja)
NO (1)	NO331682B1 (ja)
PL (1)	PL210794B1 (ja)
PT (1)	PT1426054E (ja)
RU (1)	RU2298414C2 (ja)
WO (1)	WO2003015810A1 (ja)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005000332A3 (en) *	2003-06-27	2005-03-24	Fujisawa Pharmaceutical Co	Therapeutic agent for soft tissue sarcoma
WO2005059167A1 (en) *	2003-12-18	2005-06-30	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Method for identifying histone deacetylase inhibitors
WO2005058298A3 (en) *	2003-12-10	2005-11-10	Wisconsin Alumni Res Found	Fk228 analogs and their use as hdac-inhibitors
WO2005079827A3 (en) *	2004-02-25	2005-12-08	Astellas Pharma Inc	Antitumor agent
JP2006000113A (ja) *	2004-05-20	2006-01-05	Masatomo Sakurai	漢方医療の診断に用いる遺伝子およびその利用方法
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7169801B2 (en)	2003-03-17	2007-01-30	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7314862B2 (en) *	2003-09-25	2008-01-01	Astellas Pharma Inc.	Antitumor agent
US7642253B2 (en)	2005-05-11	2010-01-05	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7642275B2 (en)	2004-12-16	2010-01-05	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7732475B2 (en)	2005-07-14	2010-06-08	Takeda San Diego, Inc.	Histone deacetylase inhibitors
KR101167601B1 (ko) *	2004-02-25	2012-07-27	아스텔라스세이야쿠 가부시키가이샤	항종양제
US8691534B2 (en)	2006-12-29	2014-04-08	Celgene Corporation	Preparation of romidepsin
US8859502B2 (en)	2010-09-13	2014-10-14	Celgene Corporation	Therapy for MLL-rearranged leukemia
US8957027B2 (en)	2006-06-08	2015-02-17	Celgene Corporation	Deacetylase inhibitor therapy
US8980825B2 (en)	2010-07-12	2015-03-17	Celgene Corporation	Romidepsin solid forms and uses thereof
US9101579B2 (en)	2012-11-14	2015-08-11	Celgene Corporation	Inhibition of drug resistant cancer cells
US9134325B2 (en)	2012-09-07	2015-09-15	Celgene Corporation	Resistance biomarkers for HDAC inhibitors
US9463215B2 (en)	2013-12-27	2016-10-11	Celgene Corporation	Romidepsin formulations and uses thereof
US9539303B2 (en)	2006-04-24	2017-01-10	Celgene Corporation	Treatment of Ras-expressing tumors

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2005521737A (ja) *	2002-04-05	2005-07-21	藤沢薬品工業株式会社	腎臓癌の治療のためのデプシペプチド
JPWO2004074478A1 (ja) *	2003-02-19	2006-06-01	アステラス製薬株式会社	ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法
US20050187148A1 (en) *	2004-02-25	2005-08-25	Yoshinori Naoe	Antitumor agent
WO2006082428A2 (en)	2005-02-03	2006-08-10	Topotarget Uk Limited	Combination therapies using hdac inhibitors
US7604939B2 (en)	2005-03-01	2009-10-20	The Regents Of The University Of Michigan	Methods of identifying active BRM expression-promoting HDAC inhibitors
PL1901729T3 (pl)	2005-05-13	2012-07-31	Topotarget Uk Ltd	Formulacje farmaceutyczne inhibitorów hdac
WO2007024574A2 (en) *	2005-08-19	2007-03-01	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Topical formulations of histone deacetylase inhibitors and methods of using the same
US8828392B2 (en)	2005-11-10	2014-09-09	Topotarget Uk Limited	Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
AU2006318652A1 (en) *	2005-11-18	2007-05-31	Gloucester Pharmaceuticals, Inc.	Metabolite derivatives of the HDAC inhibitor FK228
EP2626067A1 (en)	2006-12-26	2013-08-14	Pharmacyclics, Inc.	Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
EP2815761A1 (en) *	2006-12-29	2014-12-24	Celgene Corporation	Romidepsin-based treatments for cancer
US7838234B2 (en)	2007-01-30	2010-11-23	Pharmacyclics, Inc.	Methods for determining cancer resistance to histone deacetylase inhibitors
JP2010540426A (ja)	2007-09-25	2010-12-24	トポターゲットユーケーリミテッド	特定のヒドロキサム酸化合物の合成方法
US9492423B2 (en)	2011-09-13	2016-11-15	Pharmacyclics Llc	Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1010705A1 (en) *	1997-09-02	2000-06-21	Japan Energy Corporation	Novel cyclic tetrapeptide derivatives and medicinal use thereof
JP2001348340A (ja) *	2000-06-07	2001-12-18	Yamanouchi Pharmaceut Co Ltd	ヒストン脱アセチル化酵素阻害剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8817743D0 (en)	1988-07-26	1988-09-01	Fujisawa Pharmaceutical Co	Fr901228 substance & preparation thereof
US6030961A (en)	1997-03-11	2000-02-29	Bar-Ilan Research & Development Co., Ltd.	Oxyalkylene phosphate compounds and uses thereof
WO1999022773A2 (en) *	1997-11-05	1999-05-14	Baylor College Of Medicine	Sequences for targeting metastatic cells
JPH11335375A (ja)	1998-05-20	1999-12-07	Mitsui Chem Inc	ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
IL148497A0 (en)	1999-09-08	2002-09-12	Sloan Kettering Inst Cancer	Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
PT1438966E (pt) *	1999-12-08	2007-05-31	Cyclacel Pharmaceuticals Inc	Uso de depsipéptidos e seus congéneres como imunosupressores para tratamento de doenças infecciosas, como uma doença autoimune, reacções alérgicas ou doença hiperproliferativa da pele.
CA2317003A1 (en) *	2000-02-28	2001-08-28	Hidenori Nakajima	Gene expression potentiator
WO2002006307A1 (fr)	2000-07-17	2002-01-24	Fujisawa Pharmaceutical Co., Ltd.	Fk228 reduit et son utilisation
JP2005521737A (ja)	2002-04-05	2005-07-21	藤沢薬品工業株式会社	腎臓癌の治療のためのデプシペプチド
SI2238982T1 (sl)	2003-06-27	2013-01-31	Astellas Pharma Inc.	Terapevtsko sredstvo za mehkotkivni sarkom
US7314862B2 (en)	2003-09-25	2008-01-01	Astellas Pharma Inc.	Antitumor agent
US7951780B2 (en)	2004-02-25	2011-05-31	Astellas Pharma Inc.	Antitumor agent

2002
- 2002-08-20 RU RU2004108137/15A patent/RU2298414C2/ru not_active IP Right Cessation
- 2002-08-20 PL PL368708A patent/PL210794B1/pl unknown
- 2002-08-20 CA CA002457043A patent/CA2457043A1/en not_active Abandoned
- 2002-08-20 HU HU0400668A patent/HU229521B1/hu not_active IP Right Cessation
- 2002-08-20 MX MXPA04001612A patent/MXPA04001612A/es active IP Right Grant
- 2002-08-20 AT AT02760663T patent/ATE526029T1/de active
- 2002-08-20 JP JP2003520768A patent/JP4238728B2/ja not_active Expired - Lifetime
- 2002-08-20 ES ES02760663T patent/ES2371630T3/es not_active Expired - Lifetime
- 2002-08-20 US US10/486,833 patent/US8470783B2/en active Active
- 2002-08-20 EP EP02760663A patent/EP1426054B1/en not_active Expired - Lifetime
- 2002-08-20 DK DK02760663.1T patent/DK1426054T3/da active
- 2002-08-20 WO PCT/JP2002/008355 patent/WO2003015810A1/ja active Application Filing
- 2002-08-20 PT PT02760663T patent/PT1426054E/pt unknown
2004
- 2004-02-20 NO NO20040731A patent/NO331682B1/no not_active IP Right Cessation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1010705A1 (en) *	1997-09-02	2000-06-21	Japan Energy Corporation	Novel cyclic tetrapeptide derivatives and medicinal use thereof
JP2001348340A (ja) *	2000-06-07	2001-12-18	Yamanouchi Pharmaceut Co Ltd	ヒストン脱アセチル化酵素阻害剤

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] accession no. STN Database accession no. 2001568142 *
HAN JEUNG-WHAN ET AL.: "Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of p21WAF1/Cip1 and gelsolin", CANCER RESEARCH, vol. 60, no. 21, 1 November 2000 (2000-11-01), pages 6068 - 6074, XP002960288 *
KOMATSU YASUHIKO ET AL.: "Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity", CANCER RESEARCH, vol. 61, no. 11, 1 June 2001 (2001-06-01), pages 4459 - 4466, XP002960287 *
KOSUGI HIROSHI ET AL.: "In vivo effects of a histone deacetylase inhibitor, FK228, on human acute promyelocytic leukemia in NOD/Shi-scid/scid mice", JAPANESE JOURNAL OF CANCER RESEARCH, vol. 92, no. 5, 31 May 2001 (2001-05-31), pages 529 - 536, XP002960284 *
PIEKARZ R.L. ET AL.: "Inhibitor of histone deacetylation, depsipeptide(FR901229), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report", BLOOD, vol. 98, no. 9, 1 November 2001 (2001-11-01), pages 2865 - 2868, XP002960285 *
UEDA HIROTSUGU ET AL.: "FR901228, a novel antitumor bicyclic depsipeptide produced by chromobacterium violaceum No. 968 III. Antitumor activities on experimental tumors in mice", THE JOURNAL OF ANTIBIOTICS, vol. 47, no. 3, 25 March 1994 (1994-03-25), pages 315 - 323, XP002960289 *
WANG RUOXIANG ET AL.: "Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression", ONCOGENE, vol. 17, no. 12, 24 September 1998 (1998-09-24), pages 1503 - 1508, XP002960286 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7154002B1 (en)	2002-10-08	2006-12-26	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7399884B2 (en)	2002-10-08	2008-07-15	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7381825B2 (en)	2003-03-17	2008-06-03	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7375228B2 (en)	2003-03-17	2008-05-20	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7169801B2 (en)	2003-03-17	2007-01-30	Takeda San Diego, Inc.	Histone deacetylase inhibitors
JP2007521259A (ja) *	2003-06-27	2007-08-02	アステラス製薬株式会社	軟部肉腫治療剤
EP2238982A3 (en) *	2003-06-27	2011-03-02	Astellas Pharma Inc.	Therapeutic agent for soft tissue sarcoma
WO2005000332A3 (en) *	2003-06-27	2005-03-24	Fujisawa Pharmaceutical Co	Therapeutic agent for soft tissue sarcoma
US7056883B2 (en)	2003-06-27	2006-06-06	Astellas Pharma Inc.	Therapeutic agent for soft tissue sarcoma
US7314862B2 (en) *	2003-09-25	2008-01-01	Astellas Pharma Inc.	Antitumor agent
WO2005058298A3 (en) *	2003-12-10	2005-11-10	Wisconsin Alumni Res Found	Fk228 analogs and their use as hdac-inhibitors
WO2005059167A1 (en) *	2003-12-18	2005-06-30	Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa	Method for identifying histone deacetylase inhibitors
WO2005079827A3 (en) *	2004-02-25	2005-12-08	Astellas Pharma Inc	Antitumor agent
US8822422B2 (en)	2004-02-25	2014-09-02	Astellas Pharma Inc.	Antitumor agent
KR101167601B1 (ko) *	2004-02-25	2012-07-27	아스텔라스세이야쿠 가부시키가이샤	항종양제
US7951780B2 (en)	2004-02-25	2011-05-31	Astellas Pharma Inc.	Antitumor agent
JP2006000113A (ja) *	2004-05-20	2006-01-05	Masatomo Sakurai	漢方医療の診断に用いる遺伝子およびその利用方法
US7642275B2 (en)	2004-12-16	2010-01-05	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7642253B2 (en)	2005-05-11	2010-01-05	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7741494B2 (en)	2005-07-14	2010-06-22	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US7732475B2 (en)	2005-07-14	2010-06-08	Takeda San Diego, Inc.	Histone deacetylase inhibitors
US9539303B2 (en)	2006-04-24	2017-01-10	Celgene Corporation	Treatment of Ras-expressing tumors
US8957027B2 (en)	2006-06-08	2015-02-17	Celgene Corporation	Deacetylase inhibitor therapy
US9259452B2 (en)	2006-06-08	2016-02-16	Gelgene Corporation	Deacetylase inhibitor therapy
US8691534B2 (en)	2006-12-29	2014-04-08	Celgene Corporation	Preparation of romidepsin
US9518094B2 (en)	2010-07-12	2016-12-13	Celgene Corporation	Romidepsin solid forms and uses thereof
US8980825B2 (en)	2010-07-12	2015-03-17	Celgene Corporation	Romidepsin solid forms and uses thereof
US9624271B2 (en)	2010-07-12	2017-04-18	Celgene Corporation	Romidepsin solid forms and uses thereof
US8859502B2 (en)	2010-09-13	2014-10-14	Celgene Corporation	Therapy for MLL-rearranged leukemia
US9134325B2 (en)	2012-09-07	2015-09-15	Celgene Corporation	Resistance biomarkers for HDAC inhibitors
US9101579B2 (en)	2012-11-14	2015-08-11	Celgene Corporation	Inhibition of drug resistant cancer cells
US9468664B2 (en)	2013-12-27	2016-10-18	Celgene Corporation	Romidepsin formulations and uses thereof
US9463215B2 (en)	2013-12-27	2016-10-11	Celgene Corporation	Romidepsin formulations and uses thereof
US9782451B2 (en)	2013-12-27	2017-10-10	Celgene Corporation	Romidepsin formulations and uses thereof
US9795650B2 (en)	2013-12-27	2017-10-24	Celgene Corporation	Romidepsin formulations and uses thereof

Also Published As

Publication number	Publication date
JPWO2003015810A1 (ja)	2004-12-02
HUP0400668A3 (en)	2012-09-28
US8470783B2 (en)	2013-06-25
HU229521B1 (hu)	2014-01-28
RU2298414C2 (ru)	2007-05-10
ES2371630T3 (es)	2012-01-05
HUP0400668A2 (hu)	2005-01-28
MXPA04001612A (es)	2004-07-08
EP1426054A1 (en)	2004-06-09
NO20040731L (no)	2004-04-20
PL210794B1 (pl)	2012-03-30
US20050191713A1 (en)	2005-09-01
RU2004108137A (ru)	2005-05-10
JP4238728B2 (ja)	2009-03-18
EP1426054B1 (en)	2011-09-28
PT1426054E (pt)	2011-12-06
PL368708A1 (en)	2005-04-04
EP1426054A4 (en)	2006-09-13
CA2457043A1 (en)	2003-02-27
DK1426054T3 (da)	2011-12-12
ATE526029T1 (de)	2011-10-15
NO331682B1 (no)	2012-02-20

Legal Events

Date	Code	Title	Description
2003-02-27	AK	Designated states	Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KR KZ LK LR LS LT LU LV MA MD MG MK MW MX MZ NO NZ OM PH PL PT RO SD SE SG SI SK SL TJ TM TN TR TT UA UG US UZ VC VN YU ZA ZM Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW
2003-02-27	AL	Designated countries for regional patents	Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG
2003-04-23	121	Ep: the epo has been informed by wipo that ep was designated in this application
2003-04-24	DFPE	Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
2004-02-13	WWE	Wipo information: entry into national phase	Ref document number: 2003520768 Country of ref document: JP
2004-02-20	WWE	Wipo information: entry into national phase	Ref document number: PA/a/2004/001612 Country of ref document: MX Ref document number: 10486833 Country of ref document: US
2004-02-23	WWE	Wipo information: entry into national phase	Ref document number: 2457043 Country of ref document: CA
2004-03-02	WWE	Wipo information: entry into national phase	Ref document number: 2002760663 Country of ref document: EP
2004-06-09	WWP	Wipo information: published in national office	Ref document number: 2002760663 Country of ref document: EP

Publication	Publication Date	Title
WO2003015810A1 (fr)	2003-02-27	Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale
WO2005011734A3 (en)	2005-04-14	Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
NO20042161L (no)	2004-08-17	Inhibitorer av 11-beta-hydroksysteroid dehydrogenase type 1
WO2003042246A3 (en)	2003-09-25	Inhibitors of the notch signalling pathway for use in the treatment of cancer
EP1140840A4 (en)	2002-09-18	-G (V) -CARBOXYARYL SUBSTITUTED DIPHENYL UREASINE AS RAF KINASE INHIBITORS
AU2002302587A1 (en)	2002-11-18	Acne treatment with lipooxigenase inhibitors
EP1510221A4 (en)	2009-04-29	MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERSONS EXPRESSING OR ACTIVATING HER2 AND / OR EGFR
DK1373215T3 (da)	2006-11-13	Gelanamycinderivater egnet til behandling af cancer
TR200102110T2 (tr)	2001-10-22	Astım için formoterol ve flütikazon propiyonat kombinasyonları.
AU7490700A (en)	2001-04-17	Dosage forms and methods for providing effective reboxetine therapy with once-a-day dosing
IL175220A (en)	2010-12-30	3,5-substituted estrone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for inhibiting 17beta-hydroxysteroid dehydrogenase type i enzyme
BR0314797A (pt)	2005-07-26	Derivados da pirimidineamida e o uso dos mesmos
WO2002015921A3 (en)	2003-08-07	Methods of treating cutaneous and peripheral t-cell lymphoma by a histone deacetylase inhibitor
NO20055891L (no)	2006-02-07	Kinazolinderivater som aurorakinaseinhibitorer
WO2003103743A3 (en)	2004-07-22	MEDICAL DEVICE FOR INTRALUMINAL SUPPLY OF PHARMACEUTICAL AGENTS
YU16399A (sh)	2000-03-21	) UPOTREBA INHIBITOR H +, K+ - ATP- aze I FARMACEUTSKA FORMULACIJA ZA SIMULTANU, SEPARATNU ILI SEKVENCIJALNU UPOTREBU, KOJA SADRZI INHIBITOR H +, K+-ATP- aze I GLUKOKORTIKOID INHIBITOR H +, K+- ATP- aze
MY141007A (en)	2010-02-12	Use of an alpha-2-delta ligand for the treatment of luts
ATE489080T1 (de)	2010-12-15	Antitumorale mittel
EP1362601B8 (en)	2007-02-28	Method of examining effect of angionegesis inhibitor mediated by the inhibition of integrin expression
WO2005087206A3 (en)	2006-01-12	Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor
NO323466B1 (no)	2007-05-21	Nye kinolinyl-piperidin-4-yliden-metyl-benzamidderivater, fremgangsmate til fremstilling derav, anvendelse derav i medikamenter til behandling av smerte, samt farmasoytisk sammensetning som innbefatter slike derivater
WO2004034987A3 (en)	2004-07-15	Treatment for reactive arthritis or bursitis
WO2002102846A3 (fr)	2004-04-22	Composition pharmaceutique comprenant un agent modulateur de l'etat de polymerisation de l'actine
WO2003035048A3 (en)	2003-10-09	Methods for the treatment of osteoarthritis and compositions thereof
WO2003047697A3 (en)	2003-10-30	Use of an farsenyl protein tranferase inhibitor in combination with other antineoplastic agents for the manufacture of a medicament against cancer